Overview
- The daily 25 mg semaglutide tablet is authorized for chronic weight management, with labeling that includes reducing major cardiovascular risk in certain adults with obesity or overweight.
- In late-stage trials, participants lost about 16.6% of body weight over 64 weeks at the highest dose versus roughly 2–3% on placebo, with real-world results expected to hinge on consistent daily use.
- Patients must take the pill on an empty stomach with a small amount of water and wait 30 minutes before food, drink or other oral medicines; gastrointestinal side effects were most common, and 7% discontinued versus 6% on placebo.
- Novo Nordisk says 1.5 mg starter tablets will be available in early January 2026 under a $149 cash price, with U.S. production ramped to support supply.
- Eli Lilly’s oral orforglipron remains under FDA review with a decision anticipated in the coming months, while India’s March 2026 semaglutide patent expiry is expected to invite lower-priced generics and shift market dynamics.